Projects } TBK Capital

Pictor’s new product launch - here and in the U.S.

Further to my previous communications on Pictor, there have been some exciting developments across their human and animal health diagnostic products. 

Further to my previous communications on Pictor, there have been some exciting developments across their human and animal health diagnostic products. 
Proven success
Since the New Zealand launch, consumer feedback on the PictArray™ SARS-CoV-2 Antibody Test has demonstrated real clinical utility for both doctors and patients. One particular patient said the test has “had lifechanging results”. 

Following an extended period of illness with suspected COVID-19 but without having confirmation of infection using antigen or PCR tests, the PictArray™ SARS-CoV-2 Antibody Test confirmed a previous infection with the COVID-19 virus.  This result has allowed the patient to engage with their doctor around treatment and management as a potential Long-Covid case.

Another patient’s PictArray™ SARS-CoV-2 Antibody Test showed they had not generated protective antibodies in response to five doses of COVID-19 vaccine due to a concurrent course of immunosuppressant medication.  Based on this result, the patient’s doctor prescribed treatment with monoclonal antibodies to provide protection against the COVID-19 virus that their immune system could not produce. 

And here’s a recent article in NZ Doctor which says “The PictArray™ SARS-CoV-2 assay is the first test of its kind. It enables personalized COVID-19 assessments by detecting if a patient has antibodies from a previous infection of SARS-CoV-2 – from spike protein (SP) and nucleocapsid protein (NP) antibodies or from vaccination alone (SP antibodies only).

“It indicates whether at-risk patients have failed to mount a detectable antibody response despite vaccination or infection (SP and NP negative)”.

Animal health
Within its Animal Health division, Pictor has commenced alpha trials for their much-anticipated Johne’s disease test. This is a chronic, inflammatory intestinal immune disease in ruminants (predominantly bovines, sheep & deer) which is caused by an infection with Mycobacterium avium subspecies paratuberculosis (MAP).
In New Zealand alone, milk production losses caused by Johne’s disease is estimated at over USD$50 million annually.
The alpha trial results are expected to confirm that with multiple Johne's disease biomarkers, the Pictor test will enable subclinical detection and, consequently, more informed and effective livestock management and improved production yields both in New Zealand and globally.

Want to know more?
An Information Memorandum, an investor slide deck, and a subscription agreement are all available for intending investors.
So if you’re interested in investing, or would like more information, reply to this email, or give me a call on +64 21 902 901.

The above investment is not an offer of financial products that requires disclosure under the Financial Markets Conduct Act 2013 (Act) and is available only to wholesale investors as defined by that Act. It is intended for distribution only to selected people to whom, under the relevant laws, it can be lawfully distributed. It cannot be distributed in any other jurisdiction, or to any other people. It is not an offer or solicitations in any jurisdiction in which such offers or solicitations are not authorised, or in which the person making such offers or solicitations are not qualified to do so, or to any person to whom it is unlawful to make such offers or solicitations. Any representation to the contrary would be unlawful. No action has been taken by any person that would permit a public offering in any jurisdiction where action for that purpose would be required.


John Paine B.Sc., Dip BIA
TBK Capital Limited
Level 10,120 Albert Street
Auckland 1010, New Zealand
Phone +64 9 307 3257
Mobile +64 21 902 901

For more information, please click the contact button below to send us a message.


⇑ back to top